A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS) Clinical Trial

Official title:

Prospective, Open, Multi-center, Double Arm Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02779569
• Other study ID #: MDS-ULD-2016
• Secondary ID: ChiCTR-IPR-16008
• Status: Recruiting
• Phase: N/A
• First received: May 9, 2016
• Last updated: November 7, 2017
• Start date: March 2016
• Est. completion date: August 2019

Study information

• Verified date: May 2016
• Source: The First Affiliated Hospital with Nanjing Medical University
• Contact: Guangsheng He, MD.PhD
• Phone: 008615312052789
• Email: heguangsheng[@]medmail.com.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and clinical efficacy of ultra-low-dose decitabine in Chinese MDS

Description:

To develop a highly effective and safe protocol, a multi-center, prospective clinical trial was conducted in China, with aims to evaluate the grade III and IV hematologic toxicity and clinical efficacy of subcutaneous injection of ultra-low-dose decitabine (5 to 7 mg/m2) for treatment of myelodysplastic syndrome (MDS), while decitabine at a dose of 20 mg/m2 as a control.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: August 2019
• Est. primary completion date: March 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Men or women aged 18 to 80 years;

2. Patients at high risk of MDS assessed by International Prostate Symptom Score (IPSS);

3. Chronic myelomonocytic leukemia (CMML) patients with abnormal white blood cell counts, extremely low platelet count or organ infiltration (such as hepatomegaly, splenomegaly) that required therapy;

4. Patients at low risk of MDS identified by IPSS score who had secondary MDS, platelet count of < 20*10^9/L, no response to erythropoietin (EPO) (non-5q deletion syndrome) in the presence of disease symptoms or blood transfusion dependence, or no response to EPO/lenalidomide (5q deletion syndrome) in the presence of disease symptoms or blood transfusion dependence;

5. Patients with a Eastern Cooperative Oncology Group (ECOG) of 0 to 2;

6. Patients with an expected lifespan of over 6 months;

7. Patients with a aspartate aminotransferase (AST) of < 2.5 times higher than the normal upper limit, alanine aminotransferase (ALT) of < 2.5 times higher than the normal upper limit, total bilirubin of < 1.5 times higher than the normal upper limit, and serum creatinine of < 1.5 times higher than the normal upper limit;

8. Subjects who had recovery of toxicity, did not undergo any therapy 4 weeks prior to the first trial, and did not receive nitrosourea therapy and bone marrow transplantation 6 weeks prior to the first trial;

9. Female subjects were menopausal, underwent surgical sterilization, or had effective contraception (oral contraceptive, injectable contraceptive, intrauterine device, contraceptive patch, male sterilization) prior to enrollment and during the trial, and were negative for serum or urine pregnancy test at screening;

10. No insemination was given to male subjects during the treatment and within 2 months post-treatment;

11. Subjects complying with the study protocol;

12. Subjects that signed the informed consent, which indicated they understood the purpose, the procedure and potential benefits of the trial and were willing to participate in the trial.

Exclusion Criteria:

1. Patients that were diagnosed as acute myeloid leukemia (primitive bone marrow cell proportion of 20% or higher) or other progressive malignant diseases;

2. Patients that received treatment with other drugs within 30 days prior to the first administration of decitabine;

3. Patients that received radiotherapy within 14 days prior to the first administration of decitabine;

4. Patients with uncontrolled heart disease or congestive heart failure;

5. Patients with uncontrolled restrictive or obstructive pulmonary disease;

6. Patients with active viral, bacterial or invasive fungal infections;

7. Patients that were complicated by autoimmune hemolytic anemia or immune thrombocytopenia;

8. Patients with a history of use of azacitidine or decitabine;

9. Patients that were sero-positive for HIV;

10. Patients with mental or other disorders that cannot completely cooperate with the treatment or follow up;

11. Patients bone marrow cannot be sampled;

12. Subjects that were allergic to decitabine vehicle;

13. Pregnant or lactating women.

Related Conditions & MeSH terms

• Myelodysplastic Syndromes
• Myelodysplastic Syndromes (MDS)
• Preleukemia
• Syndrome

Intervention

Drug:
• decitabine

Locations

Country	Name	City	State
China	Zhejiang Provincial Hospital of TCM	Hangzhou	Zhejiang
China	Jiangsu Province Hospital	Nanjing	Jiangsu
China	No.303 Hospital of Chinese People's Liberation Army	Nanning	Guangxi
China	Shengjing Hospital of China Medical Univercity	Shenyang	Liaoning
China	People's Hospital of Xinjiang Uygur Autonomous Region	Urumqi	Xinjiang
China	The First Affiliated Hospital of Xi'an Jiaotong University	Xi'an	Shanxi

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital with Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Grade III and IV hematologic toxicity, according to National Cancer Institute common toxicity criteria (NCI-CTC) V3.0 criteria		8 months
Secondary	Complete response, according to International Working Group (IWG) response criteria		8 months
Secondary	Complete response (CR) rate of bone marrow, according to IWG response criteria		8 months
Secondary	Partial response (PR) rate, according to IWG response criteria		8 months
Secondary	Hematologic improvement (HI), according to IWG response criteria		8 months
Secondary	Overall response rate, defined as CR+PR+HI, according to IWG response criteria		8 months
Secondary	Cytogenetic response, according to IWG response criteria		8 months
Secondary	times of transfusion requirements	times of transfusion requirements during 8 months after enrollment	8 months
Secondary	times of hospitalization	times of hospitalization during 8 months after enrollment	8 months
Secondary	The quality of life, the quality of life will be assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQC30)		8 months